START Midwest
Midwest
Grand Rapids, MI
Accepting patients
OPN-662
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
- BET Inhibitor
- Phase 1
Accepting patients
DREAMM20
A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1/2
- Has results